Navigation Links
DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC

MIAMI--(MARKET WIRE) -- July 02, 2007 -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company") announced today that the first results from testing of a multivalent form of its botulinum toxin vaccine, BT-VACC™, have been published in the journal Infection and Immunity (Ravichandran et al., 2007, Infection and Immunity, v. 75, p. 3043 ). These results are the first that describe the protective immunity elicited by a multivalent vaccine that is active by the mucosal route. The vaccine consists of a combination of three non-toxic subunits of botulinum toxin that induced protection against the corresponding versions of the natural toxins.

The results published in Infection and Immunity show that non-toxic subunits (protein components of the natural toxin) of three of the serotypes of botulinum toxin that cause almost all instances of human disease, namely serotypes A, B, and E, can be combined and delivered via nasal administration. The combination vaccine induced antibodies in the serum of mice and protected against subsequent exposure to high doses of a combination of the natural A, B, and E serotype neurotoxins. Further, the combination vaccine can induce protection when given mucosally as a booster to animals that have been given a primary vaccine injection.

BT-VACC™ is composed of a component of what is known as the heavy chain of each of the A, B, and E serotypes. These components lack the region of the toxin that are responsible for blocking neurotransmitter functions. The subunits can bind avidly to receptors on the surface of mucosal cells and traverse lung and gastrointestinal tissue to stimulate immunity. Because the binding subunits lack the toxic part of the molecule, the vaccine is safe and stimulates antibodies in not only the blood but those antibodies that coat mucosal surfaces. It is thought that antibodies that are present in lung and gastrointestinal secretions wil
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:11/20/2009)... , NEW YORK, Nov. 20 ,, Re...h report is available in its catalogue. ,, Glo... http://www.reportlinker.com/p0164741/Global-Mark...=prnewswire&utm_medium=pr&utm_campaign=prn...sy devices includes the spring loaded core needle ...
(Date:11/20/2009)..., NATICK, Mass. and LONDON, Nov. 20 /PRNewswire...: BSX ) today announced that it has received 510...ration (FDA) and CE Mark approval to market its Wa...e treatment of malignant esophageal strictures (ob...ctable or non-resectable esophageal cancer. ,,...
(Date:11/20/2009)... , PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswire-U...mes article that questions why currently availabl...ancers are being ignored, ECRI Institute, an indep...ap to the evidence on Finasteride for Prevention ... November 13, 2009, New York Times article, " Dr...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Heartburn Drugs May Contribute to the Problem 50969 1Heartburn Drugs May Contribute to the Problem 50969 2Heartburn Drugs May Contribute to the Problem 50969 3Pharmacyclics Sets Record Date for Rights Offering 50966 1Pharmacyclics Sets Record Date for Rights Offering 50966 2Pharmacyclics Sets Record Date for Rights Offering 50966 3CareFusion Corporation Launches International Jazz Festival Series 50963 1CareFusion Corporation Launches International Jazz Festival Series 50963 2CareFusion Corporation Launches International Jazz Festival Series 50963 3CareFusion Corporation Launches International Jazz Festival Series 50963 4CareFusion Corporation Launches International Jazz Festival Series 50963 5
... (OTCBB: ORMP) ( http://www.oramed.com ), a develo... it will hold a conference call on August 6,2008 a... 2A clinical trials,of its flagship product, ORMD ... trial is focused on assessing the safety and effi... the successfully completed,Phase 1 studies in Isr...
...(OTC Bulletin Board: ANPG), reported today that it...I) announced that its EnviroTru(R),disinfectant ha...tment of,Management Services (DMS) in the State of...r, A World of Green, LLC(TM) ( http://www.aworldo...u(R) assigned under the code which now,permits Sta...
Other Medicine Technology:Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 3
(Date:11/20/2009)...ON, NJ, Nov. 20 /PRNewswire-FirstCall/ - NUCRYST P...l Meeting of Shareholders will be held on Monday, ...o consider approval of two special resolutions. Th...rize the sale of all or substantially all of the a...ded for in the asset purchase agreement dated Nove...
(Date:11/20/2009)...HINGTON, Nov. 20 The Un...he Senate to make essential changes its health ref...abortion funding and conscience protection on abor... and include strong provisions for adequate afford...h care bill an "enormous disappointment" that crea...
(Date:11/20/2009)... Senators and Congressmen in Competitive Re-...alth Care Vote , Washingt...ongressmen running for re-election next year in ra...rlie Cook, may come to regret voting for House Spe...ing to a breaking Zogby International/ O’Lea...
(Date:11/20/2009)... Nov. 20 The American D...and Drug Administration (FDA) to establish appropr.... ,, Citing concern about the safety of whiten...he benefit of professional consultation or examina...pplication of chemically based tooth whitening or ...
(Date:11/20/2009)...AIFA, Israel, November 20 /PRNewswire-FirstCall/ -... http://www.CVSLMEDICAL.COM , a leading,developer ...ay announced that,the company,s Board of Directors...rope, Canada and the Far East for its proprietary ...or all angioplasty (PCTA) procedures. , C...
Breaking Medicine News(10 mins):Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2
... new weapon is being investigated.// Scientist...edient -oligo fructose, on obese human subjects. ...the natural fiber seen in baby foods, cereals and ...ke peptide that was responsible for a feeling of s...
...munication between clinicians in the Intensive Car... significantly reduces feelings of stress,// anxie...g to a study that appears in the February 1, 2007 ...National Institutes of Health (NIH), showed that t...
...vels during women’s menstrual cycles affect the re... imaging study at the National Institute of// Ment...itutes of Health (NIH), has revealed. While w...o a phase when estrogen and progesterone are prese...
...to grant product patent for Glivec, the cancer dru...esult Novartis may not be able to conduct// their ...re the countries where Novartis conducts its resea... government could hamper the launch of their paten...
...re has been a marked increase in allergic reaction...ed eight times during a 30 year period.// Teenager...sporting different hair colors, in keeping with a ...esearchers are pressing for a wider debate about t...
...of Michigan Medical Center have, for the first tim.../ Their work indicates that these cells are likely...ression, and metastasis that define this deadly ca...atic cancer in half of mice tested. They also foun...
Other Medicine News:Health News:Communication in the ICU to Be Strengthened 2Health News:Communication in the ICU to Be Strengthened 3Health News:NIMH Studies Woman’s Hormonal Cycl 2Health News:Scientists Identify Pancreatic Cancer Stem Cells 2Health News:Scientists Identify Pancreatic Cancer Stem Cells 3
Bandeau Bra
Medical Cotton Bra
Compression Bra
Universal Breast Augmentation Support
Medicine Products: